ROCKVILLE, MD and SHENZHEN, CHINA, November 2, 2023—HighTide Therapeutics, Inc. (“HighTide”), a globally integrated biopharmaceutical company specializing in the development of multifunctional, multi-targeted therapies for metabolic and digestive diseases

HighTide Therapeutics, Inc. (“HighTide”), a globally integrated biopharmaceutical company specializing in the development of multifunctional multi-targeted therapies for metabolic and digestive diseases, today announces that the company’s founder and CEO,

ROCKVILLE, MD and SHENZHEN, CHINA, October 20, 2023— HighTide Therapeutics, Inc. (HighTide), a biopharmaceutical company developing novel multifunctional multi-targeted therapies for metabolic

ROCKVILLE, MD and SHENZHEN, CHINA, October 11, 2023 — HighTide Therapeutics, Inc. (“HighTide”), a biopharmaceutical company developing novel multifunctional multi-targeted therapies for metabolic and digestive diseases

HighTide Therapeutics, Inc. (“HighTide”) was invited to present at the Office for Attracting Strategic Enterprises (OASES) launching ceremony hosted by the Hong Kong government. HighTide, a company focused on the discovery and development o

ROCKVILLE, MD and SHENZHEN, CHINA, October 3rd, 2023— HighTide Therapeutics, Inc. (“HighTide”) announces that the primary findings from the Phase 2 clinical trial of berberine ursodeoxycholate (HTD1801)